International Niemann–Pick Disease Alliance
Vtesse, Inc. Expands Scientific Advisory Board, Fills Key Patient Advocacy Position to Prepare for Further Clinical Development of VTS-270 in Niemann-Pick Disease Type C (NPC)
Gaithersburg, MD, June 15, 2015 – Vtesse, Inc., a rare disease company focused on developing drugs for Niemann-Pick Disease Type C (NPC) and other severe diseases with great unmet need, announced today the expansion of its Scientific Advisory Board (SAB) and the filling of a key staff position in patient advocacy.
The two new SAB members include Björn Hoffstedt, MD, PhD, Managing Director, AB Clinical Development GmbH, and Heiko Runz, MD, Director of Genetics at Merck Research Laboratories in Boston.
View the full press release on their website.